Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Low-Intensity Exercise in Mice Is Sufficient to Protect Retinal Function During Light-Induced Retinal Degeneration.

Mees LM, Coulter MM, Chrenek MA, Motz CT, Landis EG, Boatright JH, Pardue MT.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1328-1335. doi: 10.1167/iovs.18-25883.

2.

Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection.

Daruich A, Le Rouzic Q, Jonet L, Naud MC, Kowalczuk L, Pournaras JA, Boatright JH, Thomas A, Turck N, Moulin A, Behar-Cohen F, Picard E.

Sci Adv. 2019 Jan 9;5(1):eaau9940. doi: 10.1126/sciadv.aau9940. eCollection 2019 Jan.

3.

Set screw homogenization of murine ocular tissue, including the whole eye.

Gooding SW, Chrenek MA, Ferdous S, Nickerson JM, Boatright JH.

Mol Vis. 2018 Oct 26;24:690-699. eCollection 2018.

4.

Differential Exon Expression in a Large Family of Retinal Genes Is Regulated by a Single Trans Locus.

Wang J, Struebing FL, Ferdous S, Donaldson K, Boatright JH, Geisert EE, Nickerson JM.

Adv Exp Med Biol. 2018;1074:413-420. doi: 10.1007/978-3-319-75402-4_51.

PMID:
29721971
5.

TrkB signalling pathway mediates the protective effects of exercise in the diabetic rat retina.

Allen RS, Hanif AM, Gogniat MA, Prall BC, Haider R, Aung MH, Prunty MC, Mees LM, Coulter MM, Motz CT, Boatright JH, Pardue MT.

Eur J Neurosci. 2018 May;47(10):1254-1265. doi: 10.1111/ejn.13909. Epub 2018 Apr 3.

6.

Daily visual stimulation in the critical period enhances multiple aspects of vision through BDNF-mediated pathways in the mouse retina.

Mui AM, Yang V, Aung MH, Fu J, Adekunle AN, Prall BC, Sidhu CS, Park HN, Boatright JH, Iuvone PM, Pardue MT.

PLoS One. 2018 Feb 6;13(2):e0192435. doi: 10.1371/journal.pone.0192435. eCollection 2018.

7.

Xanthohumol Protects Morphology and Function in a Mouse Model of Retinal Degeneration.

Henneman NF, Foster SL, Chrenek MA, Sellers JT, Wright CB, Schmidt RH, Nickerson JM, Boatright JH.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):45-53. doi: 10.1167/iovs.17-22132.

8.

Aerobic Exercise as an Adjuvant to Aphasia Therapy: Theory, Preliminary Findings, and Future Directions.

Harnish SM, Rodriguez AD, Blackett DS, Gregory C, Seeds L, Boatright JH, Crosson B.

Clin Ther. 2018 Jan;40(1):35-48.e6. doi: 10.1016/j.clinthera.2017.12.002. Epub 2017 Dec 23.

PMID:
29277374
9.

IRBP deficiency permits precocious ocular development and myopia.

Markand S, Baskin NL, Chakraborty R, Landis E, Wetzstein SA, Donaldson KJ, Priyadarshani P, Alderson SE, Sidhu CS, Boatright JH, Iuvone PM, Pardue MT, Nickerson JM.

Mol Vis. 2016 Oct 27;22:1291-1308. eCollection 2016.

10.

Analysis of RPE morphometry in human eyes.

Bhatia SK, Rashid A, Chrenek MA, Zhang Q, Bruce BB, Klein M, Boatright JH, Jiang Y, Grossniklaus HE, Nickerson JM.

Mol Vis. 2016 Jul 30;22:898-916. eCollection 2016.

11.

Exercise as Gene Therapy: BDNF and DNA Damage Repair.

Schmidt RH, Nickerson JM, Boatright JH.

Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):309-11. doi: 10.1097/APO.0000000000000226. Review.

12.

Clustered Regularly Interspaced Short Palindromic Repeats: Challenges in Treating Retinal Disease.

Chrenek MA, Nickerson JM, Boatright JH.

Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug;5(4):304-8. doi: 10.1097/APO.0000000000000225. Review.

13.

Neuroprotective Effects of Voluntary Exercise in an Inherited Retinal Degeneration Mouse Model.

Hanif AM, Lawson EC, Prunty M, Gogniat M, Aung MH, Chakraborty R, Boatright JH, Pardue MT.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6839-46. doi: 10.1167/iovs.15-16792.

14.

RPE Cell and Sheet Properties in Normal and Diseased Eyes.

Rashid A, Bhatia SK, Mazzitello KI, Chrenek MA, Zhang Q, Boatright JH, Grossniklaus HE, Jiang Y, Nickerson JM.

Adv Exp Med Biol. 2016;854:757-63. doi: 10.1007/978-3-319-17121-0_101.

15.

Exercise and Cyclic Light Preconditioning Protect Against Light-Induced Retinal Degeneration and Evoke Similar Gene Expression Patterns.

Chrenek MA, Sellers JT, Lawson EC, Cunha PP, Johnson JL, Girardot PE, Kendall C, Han MK, Hanif A, Ciavatta VT, Gogniat MA, Nickerson JM, Pardue MT, Boatright JH.

Adv Exp Med Biol. 2016;854:443-8. doi: 10.1007/978-3-319-17121-0_59.

16.

Tauroursodeoxycholic Acid Protects Retinal Function and Structure in rd1 Mice.

Lawson EC, Bhatia SK, Han MK, Aung MH, Ciavatta V, Boatright JH, Pardue MT.

Adv Exp Med Biol. 2016;854:431-6. doi: 10.1007/978-3-319-17121-0_57.

PMID:
26427442
17.

In Vivo Imaging of Retinal Oxidative Stress Using a Reactive Oxygen Species-Activated Fluorescent Probe.

Prunty MC, Aung MH, Hanif AM, Allen RS, Chrenek MA, Boatright JH, Thule PM, Kundu K, Murthy N, Pardue MT.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5862-70. doi: 10.1167/iovs.15-16810.

18.

Potential Role of Exercise in Retinal Health.

Pardue MT, Chrenek MA, Schmidt RH, Nickerson JM, Boatright JH.

Prog Mol Biol Transl Sci. 2015;134:491-502. doi: 10.1016/bs.pmbts.2015.06.011. Epub 2015 Jul 17. Review.

PMID:
26310173
19.

Gram-scale, chemoselective synthesis of N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (HIOC).

Setterholm NA, McDonald FE, Boatright JH, Iuvone PM.

Tetrahedron Lett. 2015 Jun 3;56(23):3413-3415.

20.

Progesterone treatment in two rat models of ocular ischemia.

Allen RS, Olsen TW, Sayeed I, Cale HA, Morrison KC, Oumarbaeva Y, Lucaciu I, Boatright JH, Pardue MT, Stein DG.

Invest Ophthalmol Vis Sci. 2015 May;56(5):2880-91. doi: 10.1167/iovs.14-16070.

21.

Methodologies for analysis of patterning in the mouse RPE sheet.

Boatright JH, Dalal N, Chrenek MA, Gardner C, Ziesel A, Jiang Y, Grossniklaus HE, Nickerson JM.

Mol Vis. 2015 Jan 15;21:40-60. eCollection 2015.

22.

N-acetylserotonin: circadian activation of the BDNF receptor and neuroprotection in the retina and brain.

Iuvone PM, Boatright JH, Tosini G, Ye K.

Adv Exp Med Biol. 2014;801:765-71. doi: 10.1007/978-1-4614-3209-8_96.

23.

Analysis of mouse RPE sheet morphology gives discriminatory categories.

Jiang Y, Qi X, Chrenek MA, Gardner C, Dalal N, Boatright JH, Grossniklaus HE, Nickerson JM.

Adv Exp Med Biol. 2014;801:601-7. doi: 10.1007/978-1-4614-3209-8_76.

24.

The Rpe65 rd12 allele exerts a semidominant negative effect on vision in mice.

Wright CB, Chrenek MA, Feng W, Getz SE, Duncan T, Pardue MT, Feng Y, Redmond TM, Boatright JH, Nickerson JM.

Invest Ophthalmol Vis Sci. 2014 Apr 17;55(4):2500-15. doi: 10.1167/iovs.13-13574.

25.

Aerobic exercise protects retinal function and structure from light-induced retinal degeneration.

Lawson EC, Han MK, Sellers JT, Chrenek MA, Hanif A, Gogniat MA, Boatright JH, Pardue MT.

J Neurosci. 2014 Feb 12;34(7):2406-12. doi: 10.1523/JNEUROSCI.2062-13.2014.

26.

Severity of middle cerebral artery occlusion determines retinal deficits in rats.

Allen RS, Sayeed I, Cale HA, Morrison KC, Boatright JH, Pardue MT, Stein DG.

Exp Neurol. 2014 Apr;254:206-15. doi: 10.1016/j.expneurol.2014.02.005. Epub 2014 Feb 8.

27.

DNA delivery in adult mouse eyes: an update with corneal outcomes.

Nickerson JM, Getz SE, Sellers JT, Chrenek MA, Goodman P, Bernal CJ, Boatright JH.

Methods Mol Biol. 2014;1121:165-77. doi: 10.1007/978-1-4614-9632-8_15.

28.

Functional principal component analysis reveals discriminating categories of retinal pigment epithelial morphology in mice.

Jiang Y, Qi X, Chrenek MA, Gardner C, Boatright JH, Grossniklaus HE, Nickerson JM.

Invest Ophthalmol Vis Sci. 2013 Nov 5;54(12):7274-83. doi: 10.1167/iovs.13-12450.

29.

Complementation test of Rpe65 knockout and tvrm148.

Wright CB, Chrenek MA, Foster SL, Duncan T, Redmond TM, Pardue MT, Boatright JH, Nickerson JM.

Invest Ophthalmol Vis Sci. 2013 Jul 30;54(7):5111-22. doi: 10.1167/iovs.13-12336.

30.

Is the melatonin receptor type 1 involved in the pathogenesis of glaucoma?

Tosini G, Iuvone M, Boatright JH.

J Glaucoma. 2013 Jun-Jul;22 Suppl 5:S49-50. doi: 10.1097/IJG.0b013e3182934bb4. Review. Erratum in: J Glaucoma. 2013 Sep;22(7):598. Iuvone, Michael [added].

31.

Subretinal delivery and electroporation in pigmented and nonpigmented adult mouse eyes.

Nickerson JM, Goodman P, Chrenek MA, Bernal CJ, Berglin L, Redmond TM, Boatright JH.

Methods Mol Biol. 2012;884:53-69. doi: 10.1007/978-1-61779-848-1_4.

32.

Analysis of the RPE sheet in the rd10 retinal degeneration model.

Chrenek MA, Dalal N, Gardner C, Grossniklaus H, Jiang Y, Boatright JH, Nickerson JM.

Adv Exp Med Biol. 2012;723:641-7. doi: 10.1007/978-1-4614-0631-0_81. No abstract available.

33.

Exaggerated eye growth in IRBP-deficient mice in early development.

Wisard J, Faulkner A, Chrenek MA, Waxweiler T, Waxweiler W, Donmoyer C, Liou GI, Craft CM, Schmid GF, Boatright JH, Pardue MT, Nickerson JM.

Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5804-11. doi: 10.1167/iovs.10-7129.

34.

Retinal function and structure in Ant1-deficient mice.

Phillips MJ, Webb-Wood S, Faulkner AE, Jabbar SB, Biousse V, Newman NJ, Do VT, Boatright JH, Wallace DC, Pardue MT.

Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6744-52. doi: 10.1167/iovs.10-5421. Epub 2010 Jul 29.

35.

Non-contact measurement of linear external dimensions of the mouse eye.

Wisard J, Chrenek MA, Wright C, Dalal N, Pardue MT, Boatright JH, Nickerson JM.

J Neurosci Methods. 2010 Mar 30;187(2):156-66. doi: 10.1016/j.jneumeth.2010.01.006. Epub 2010 Jan 11.

36.

Bile acids in treatment of ocular disease.

Boatright JH, Nickerson JM, Moring AG, Pardue MT.

J Ocul Biol Dis Infor. 2009 Sep;2(3):149-159. Epub 2009 Aug 27.

37.

Technical brief: subretinal injection and electroporation into adult mouse eyes.

Johnson CJ, Berglin L, Chrenek MA, Redmond TM, Boatright JH, Nickerson JM.

Mol Vis. 2008;14:2211-26. Epub 2008 Dec 5.

38.

Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Edelhauser HF, Boatright JH, Nickerson JM; Third ARVO/Pfizer Research Institute Working Group.

Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4712-20. doi: 10.1167/iovs.08-1904. Epub 2008 Aug 15. No abstract available.

39.

AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation.

Pang JJ, Boye SL, Kumar A, Dinculescu A, Deng W, Li J, Li Q, Rani A, Foster TC, Chang B, Hawes NL, Boatright JH, Hauswirth WW.

Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4278-83. doi: 10.1167/iovs.07-1622. Epub 2008 Jun 27.

40.

Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30.

Phillips MJ, Walker TA, Choi HY, Faulkner AE, Kim MK, Sidney SS, Boyd AP, Nickerson JM, Boatright JH, Pardue MT.

Invest Ophthalmol Vis Sci. 2008 May;49(5):2148-55. doi: 10.1167/iovs.07-1012.

41.

Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina.

Andrieu-Soler C, Halhal M, Boatright JH, Padove SA, Nickerson JM, Stodulkova E, Stewart RE, Ciavatta VT, Doat M, Jeanny JC, de Bizemont T, Sennlaub F, Courtois Y, Behar-Cohen F.

Mol Vis. 2007 May 2;13:692-706.

42.

Two mouse retinal degenerations caused by missense mutations in the beta-subunit of rod cGMP phosphodiesterase gene.

Chang B, Hawes NL, Pardue MT, German AM, Hurd RE, Davisson MT, Nusinowitz S, Rengarajan K, Boyd AP, Sidney SS, Phillips MJ, Stewart RE, Chaudhury R, Nickerson JM, Heckenlively JR, Boatright JH.

Vision Res. 2007 Mar;47(5):624-33. Epub 2007 Jan 30.

43.

Tool from ancient pharmacopoeia prevents vision loss.

Boatright JH, Moring AG, McElroy C, Phillips MJ, Do VT, Chang B, Hawes NL, Boyd AP, Sidney SS, Stewart RE, Minear SC, Chaudhury R, Ciavatta VT, Rodrigues CM, Steer CJ, Nickerson JM, Pardue MT.

Mol Vis. 2006 Dec 29;12:1706-14.

44.

Mouse retina has oligonucleotide-induced gene repair activity.

Ciavatta VT, Padove SA, Boatright JH, Nickerson JM.

Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2291-9.

PMID:
15980213
45.

Retinoid processing proteins in the ocular ciliary epithelium.

Salvador-Silva M, Ghosh S, Bertazolli-Filho R, Boatright JH, Nickerson JM, Garwin GG, Saari JC, Coca-Prados M.

Mol Vis. 2005 May 18;11:356-65.

46.

Delivery of several forms of DNA, DNA-RNA hybrids, and dyes across human sclera by electrical fields.

Davies JB, Ciavatta VT, Boatright JH, Nickerson JM.

Mol Vis. 2003 Oct 15;9:569-78.

47.

Targeting degradation of RNA by RNase H using DNA hairpins.

Li J, Bourdelat-Parks B, Boatright JH, Wartell RM.

Biochemistry. 2003 Sep 23;42(37):10945-54.

PMID:
12974629
48.

The effect of retinoids and butyrate on the expression of CRX and IRBP in retinoblastoma cells.

Boatright JH, Stodulkova E, Do VT, Padove SA, Nguyen HT, Borst DE, Nickerson JM.

Vision Res. 2002 Apr;42(8):933-8.

49.
50.

Endogenous CRX expression and IRBP promoter activity in retinoblastoma cells.

Boatright JH, Borst DE, Stodulkova E, Nickerson JM.

Brain Res. 2001 Oct 19;916(1-2):136-42.

PMID:
11597600

Supplemental Content

Loading ...
Support Center